BGB-283 Deemed Effective in Phase I Study

In a Phase I trial, BGB-283, which targets the RAF protein family, demonstrated safety and tolerability, as well as efficacy, in treating patients with various solid tumors that have mutations in BRAF,Lifirafenib KRAS, and NRAS.